Lin Zhiwu, Wu Liang, Yu Yang, Jiang Jiudong, Yang Yanchun, Xiao Guibao
Department of Thoracic Surgery, Ziyang Central Hospital, Ziyang, China.
Department of Infectious Diseases, Ziyang Central Hospital, Ziyang, China.
Front Pharmacol. 2025 Jun 5;16:1608733. doi: 10.3389/fphar.2025.1608733. eCollection 2025.
Osimertinib is a third-generation irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively targets EGFR-TKI-sensitive mutations, thereby inhibiting tumor cell proliferation, migration, and invasion. Herein, we present a case of osimertinib-induced interstitial lung disease (ILD) in an 80-year-old woman with EGFR-mutated lung adenocarcinoma. The patient was treated with osimertinib as first-line therapy for metastatic non-small cell lung cancer (NSCLC). On day 45 of treatment, she experienced acute onset of severe dyspnea, which rapidly progressed to diffuse bilateral pulmonary consolidation and profound hypoxemia. Despite discontinuation of osimertinib and administration of aggressive supportive care, her clinical condition continued to deteriorate, ultimately resulting in a fatal outcome. This case underscores the importance of monitoring respiratory symptoms in patients receiving EGFR-TKIs, promptly diagnosing ILD, and implementing early intervention to mitigate adverse outcomes.
奥希替尼是一种第三代不可逆表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI），它选择性地靶向EGFR-TKI敏感突变，从而抑制肿瘤细胞增殖、迁移和侵袭。在此，我们报告一例80岁患有EGFR突变肺腺癌的女性患者发生奥希替尼诱导的间质性肺病（ILD）的病例。该患者接受奥希替尼作为转移性非小细胞肺癌（NSCLC）的一线治疗。在治疗的第45天，她突然出现严重呼吸困难，迅速发展为双侧肺部弥漫性实变和严重低氧血症。尽管停用了奥希替尼并给予积极的支持治疗，她的临床状况仍持续恶化，最终导致死亡。该病例强调了在接受EGFR-TKIs治疗的患者中监测呼吸道症状、及时诊断ILD以及实施早期干预以减轻不良后果的重要性。
